-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $44

Benzinga·04/14/2026 13:45:10
Listen to the news
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $39 to $44.